Spyre Therapeutics (SYRE) Other Non-Current Assets (2015 - 2025)

Spyre Therapeutics (SYRE) has 11 years of Other Non-Current Assets data on file, last reported at $10000.0 in Q1 2025.

• Quarterly Other Non-Current Assets changed 0.0% year-over-year to $10000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $10000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $10000.0, up 11.11% from the prior year.
• Other Non-Current Assets was little changed at $10000.0 in Q1 2025, from $10000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q2 2021 to a low of $9000.0 in Q4 2023.
• A 5-year average of $904562.5 and a median of $824500.0 in 2021 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets surged 1906.52% — and 2023, when it slumped 99.42%.
• Tracing SYRE's Other Non-Current Assets over 5 years: stood at $1.8 million in 2021, then declined by 15.51% to $1.6 million in 2022, then tumbled by 99.42% to $9000.0 in 2023, then rose by 11.11% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
• The last three Other Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $321000.0 (Q2 2024), per Business Quant data.